Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will report earnings of ($0.08) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Opko Health’s earnings, with estimates ranging from ($0.10) to ($0.05). Opko Health reported earnings per share of ($0.04) in the same quarter last year, which suggests a negative year over year growth rate of 100%. The company is scheduled to announce its next quarterly earnings report on Wednesday, March 7th.
According to Zacks, analysts expect that Opko Health will report full year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.34) to ($0.22). For the next fiscal year, analysts forecast that the business will report earnings of ($0.17) per share, with EPS estimates ranging from ($0.24) to ($0.06). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Opko Health.
Several equities analysts have recently commented on OPK shares. BidaskClub cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 10th. Zacks Investment Research cut shares of Opko Health from a “hold” rating to a “sell” rating in a report on Thursday, January 11th. Finally, Cantor Fitzgerald set a $20.00 price target on shares of Opko Health and gave the company a “buy” rating in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $13.34.
Shares of Opko Health (OPK) traded down $0.11 during trading hours on Wednesday, reaching $3.85. 2,463,500 shares of the company’s stock traded hands, compared to its average volume of 4,748,437. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. Opko Health has a 52 week low of $3.61 and a 52 week high of $8.92. The firm has a market cap of $2,150.00, a P/E ratio of -20.26 and a beta of 1.42.
In related news, CEO Phillip Md Et Al Frost purchased 185,000 shares of the stock in a transaction dated Friday, February 9th. The shares were acquired at an average cost of $3.83 per share, for a total transaction of $708,550.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $11,754,082.33. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have bought 688,000 shares of company stock worth $2,970,260. 40.19% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of the company. Ellington Management Group LLC bought a new stake in Opko Health in the fourth quarter worth $112,000. Crossmark Global Holdings Inc. bought a new stake in Opko Health in the third quarter worth $118,000. State of Alaska Department of Revenue bought a new stake in Opko Health in the fourth quarter worth $144,000. The Manufacturers Life Insurance Company boosted its holdings in Opko Health by 7.9% in the second quarter. The Manufacturers Life Insurance Company now owns 22,535 shares of the biotechnology company’s stock worth $149,000 after purchasing an additional 1,657 shares in the last quarter. Finally, First Trust Advisors LP bought a new stake in Opko Health in the fourth quarter worth $154,000. Institutional investors and hedge funds own 22.22% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Opko Health Inc. (OPK) Will Announce Earnings of -$0.08 Per Share” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://ledgergazette.com/2018/02/19/analysts-anticipate-opko-health-inc-opk-will-announce-earnings-of-0-08-per-share.html.
Opko Health Company Profile
OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.